PSY156 - QUIDS IN? – A REVIEW OF WHETHER POTENTIAL BLOCKBUSTER SAVINGS FROM BIOSIMILAR ADALIMUMAB SHOULD BE REINVESTED IN OTHER DISEASE AREAS? | Publicación